X

 

We would like to inform you that Viatris, the marketing authorisation holder for Creon® has decided to increase the capsule length of Creon® 25000 from 21.7mm to 24.2mm. The diameter of the capsule will not change.

The new size of Creon® 25000 capsule does not affect the efficacy of the product and should not have an impact on the patient’s ability to swallow the capsules whole.

Keywords..

You are leaving the Creon® patient website

You are now connecting to a website that is neither owned nor under the control of Viatris. Viatris is not responsible for the content of this site or any further links.
Please press OK to proceed or BACK to return to the Creon® patient website.
BACK
OK

You will now leave the Creon patient website and go to the Creon Track site where you can join the Creon Track patient support programme

Would you like to proceed to the Creon Track registration website?

OK
NO
If you get any side effects or have a device failure, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. Please report side effects or device failures with any medicine or vaccine to the medicines regulator MHRA through the Yellow Card Scheme.
It is easiest and quickest to report side effects and device failures online via the Yellow Card website: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Alternatively, prepaid Yellow Cards for reporting are available by writing to FREEPOST YELLOW CARD (no other address details necessary), by emailing yellowcard@mhra.gov.uk, by telephoning the Commission on Human Medicines (CHM) free phone line: 0800-731-6789, or by downloading and printing a form from the Yellow Card section of the MHRA website. You can also report side effects and device failures direct to the marketing authorisation holder at pv.uk@viatris.com.

Viatris UK Healthcare Limited (company registration number 09189103), an English company with a registered office address at 20 Station Close, Potters Bar, Hertfordshire, EN6 1TL (VAT - 421 623 781).

Creon® is indicated for the treatment of pancreatic exocrine insufficiency.

We recommend that you read the full patient information leaflets carefully before using Creon® 

CRE-2021-0782  April 2023

This website is owned and managed by Viatris. For more information visit viatris.co.uk

Copyright © 2023 Viatris Inc. All rights reserved.